System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Masakazu Toi is an expert in Oncology at Tokyo Metropolitan Komagome Hospital (Japan). As of October 2026, ScienceLeadR ranks Masakazu Toi in the top 1% of experts worldwide for Breast Neoplasms and Breast Diseases. Masakazu Toi has authored 1,029 publications, the most recent in 2026, and is an investigator in 21 clinical trials, 1 of them ongoing. SLR score: 3,944 (community average: 125). How the SLR is computed.

LeadR Profile

Masakazu Toi Tokyo Metropolitan Komagome Hospital Japan
3 944 ScienceLeadR Reputation 3944

Unlock

Register Login
Network Map

Oncology

Subspecialties: Nuclear Medicine - Public Health - Dermatology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1988 - 2026
Source: PubMed

Tokyo Metropolitan Komagome Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1029

Citations

Citations: 46 585 1st author: 100 Last author: 379 Unique author: 16

Main journals

Cancer Res 127
Ann Oncol 70
Breast Cancer 64
J Clin Oncol 62
Gan To Kagaku Ryoho 42

Best Journals

Ann Oncol 32
J Clin Oncol 21
Lancet Oncol 20

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Accelerated Pancreatic Volume Loss as a Potential Pre-Diagnostic Imaging Biomarker for Pancreatic Cancer Risk Enrichment: An AI-Assisted Volumetric Study.
PMID 42795025 — pancreatic neoplasms, risk assessment, neoplasms, biomarkers, diagnostic imaging, carcinogenesis, artificial intelligence, tissues, tumor microenvironment		Cancers (Basel)20260
Correction: Initial activities and prospects of MIRAY1: a youth-driven, society-endorsed initiative to cultivate future breast cancer physicians.
PMID 42701976 — breast neoplasms, neoplasms, breast, physicians		Breast Cancer20260
A case of ER-positive, HER2-negative metastatic breast cancer with high tumor mutation burden achieving complete response to pembrolizumab monotherapy.
PMID 42491212 — breast neoplasms, tomography, neoplasms, positron emission tomography computed tomography, breast, therapeutics, mutation		Int Cancer Conf J20260
Initial activities and prospects of MIRAY1: a youth-driven, society-endorsed initiative to cultivate future breast cancer physicians.
PMID 42467393 — breast neoplasms, neoplasms, breast, physicians, education, workforce		Breast Cancer20260
Novel strategies to overcome the blood-brain barrier in triple-negative breast cancer brain metastases.
PMID 42372753 — blood-brain barrier, brain neoplasms, triple negative breast neoplasms, blood, breast neoplasms, brain, neoplasms, neoplasm metastasis, breast, therapeutics		Lancet Oncol Top journal20260

Clinical Studies 21

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 18
Phase 2 2
Phase 1/Phase 2 1

By status:

Completed 14
Active not recruiting 6
Recruiting 1

By type:

Interventional 21

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 1
multicentric5to9 0
multicentricup10 17

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Trastuzumab Deruxtecan (T DXd) With or Without Pertuzumab Versus Taxane Trastuzumab and Pertuzumab in HER2 positive Metastatic Breast Cancer (DESTINY Breast09)
NCT04784715 — antineoplastic agents, phytogenic, breast neoplasms, docetaxel, paclitaxel, pharmaceutical preparations, antineoplastic agents, neoplasms, molecular mechanisms of pharmacological action, neoplasm metastasis, breast, infusions, intravenous, breast diseases, trastuzumab		Phase 3Active not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS